Andere Sprachen Soligenix, Inc.

Aktien

A3D506

US8342235053

SNGX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
0,415 ^USD	-2,81 %		-3,71 %	-45,19 %

25.04.	Soligenix erweitert Patentschutz für seine Filovirus-Impfstoff-Plattform auf das Vereinigte Königreich und Südafrika	CI
03.04.	Soligenix gibt Einigung mit der Europäischen Arzneimittelagentur über das Design der zweiten bestätigenden Placebo-kontrollierten Studie für Hybryte? bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa	25.04.
Soligenix Announces Pricing of $4.75 Million Public Offering	18.04.
Sector Update: Health Care Stocks Softer Late Afternoon	15.04.
Sector Update: Health Care Stocks Gain Monday Afternoon	15.04.
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation	15.04.
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA	15.04.
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection	15.04.
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection	11.04.
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency	03.04.
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency	03.04.
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15.03.
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results	15.03.
Soligenix Announces Formation of Beh et s Disease Medical Advisory Board	09.02.
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board	08.02.
Soligenix to Present at The Microcap Conference	25.01.
FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behcet's Disease	09.01.
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	08.01.
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	08.01.
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis	04.01.
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis	04.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Soligenix, Inc.

Aktien

A3D506

US8342235053

SNGX

Andere Sprachen

Filter